Anti-Human BCL-2 (124)- FITC

BCL-2 is a mitochondrial membrane protein, also found in the nuclear envelope and to a lesser degree in the cell membrane, that is detected in lymphocytes, T cells, B cells, primary lymphoid follicles, the mantle zone of secondary follicles, non-lymphoid hematopoietic precursors such as myeloid cells, exocrine gland duct cells, uterine smooth muscle, endometrial glands, thyroid follicles, prostatic glands, breast lobules, fetal epithelial germinative regions, placental trophoblast, endocrine cells and neurons as well as follicular non-Hodgkin?s lymphomas and a variety of other B cell lymphomas and epithelial neoplasms.

0.2 mg/ml

Fluorescein (FITC)

This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Peptide sequence corresponding to residues 41-54 of Human BCL-2

BCL-2 is a member of a protein family that regulates apoptosis, with some members inducing (proapoptotic) and others inhibiting (antiapoptotic) apoptosis 1. BCL-2 acts as an antiapoptotic protein that prevents apoptosis and promotes survival in response to many cell stresses and cytotoxic chemicals 2 via the mitochondria-mediated intrinsic apoptosis pathway 1. BCL-2 is also an important oncogene whose overexpression is common in hematological malignancies such as follicular lymphoma, chronic lymphocytic leukemia, mantle cell leukemia and Waldenstr?m's macroglobulinemia 1 as well as breast cancer 3. As such, BCL-2 is a target for inhibition in cancer immunotherapy. Additionally, BCL-2 is involved in cardiac hypertrophy and has been suggested as a potential therapeutic target for clinical management 4. Clone 124 was generated by immunizing mice with a synthetic peptide corresponding to amino acids 41 to 54 (GAAPAPGIFSSQPG) of BCL-2 conjugated to thyroglobulin 5. Sera were screened on cryostat sections of human tonsil and on a follicular lymphoma with a known 14;18 translocation. Cell fusion and hybridoma lines were produced by conventional technology. 124 recognizes BCL-2 by Western blotting under both reducing and non-reducing conditions.

596

Bcl-2